Tanashyan M M, Maksimova M Yu, Shabalina A A, Fedin P A, Medvedev R B, Bolotova T A
Research Center of Neurology, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(10):14-21. doi: 10.17116/jnevro202012010114.
To evaluate the efficacy of meldonium (mildronat) in patients with chronic cerebral vascular disease (CVD).
An open comparative study of the clinical efficacy of meldonium (mildronat) in patients with chronic CVD caused by arterial hypertension and atherosclerosis was conducted. The main group included 30 (60%) patients who were prescribed meldonium (mildronat) at a dose of 1000 mg per day in addition to routine basic therapy. The control group was consisted of 20 (40%) patients who received routine basic therapy only. The duration of the study was 60 days. To evaluate the clinical efficacy of the meldonium (mildronat), the main subjective clinical symptoms, neurological, psychoemotional and cognitive status, quality of life were assessed when patients were included in the study (), on the 11th and 60th days from the start of treatment. To assess the meldonium (mildronat) effect on the endothelium vascular wall, asymmetric dimethylarginine (ADMA), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and endothelin-1 were determined in the blood when patients were included in the study, on the 11th and 60th days from the start of treatment.
Meldonium (mildronat) has a positive therapeutic effect on the main clinical symptoms and cognitive functions which appears in increasing the quickness of mental activity, improving short-term and operative memory, increasing the resistance of mental processes and memory traces to interfering influences, and improving cognitive evoked potentials P300 results. Meldonium (mildronat) therapy leads to the decrease in the level of state and trait anxiety. The quality of life of patients treated with meldonium (mildronat) increases due to the physical and mental components. The effect of meldonium (mildronat) on the decrease in endothelin-1 and PAI-1 levels, which indicates the antitrombogenic effect of the drug, has been identified.
Nootropic, anxiolytic and antitrombogenic effects of meldonium (mildronat) in patients with chronic CVD are demonstrated that makes it possible to recommend this drug for widespread use by specialists in clinical practice.
评估米多君（米多君）对慢性脑血管疾病（CVD）患者的疗效。
对米多君（米多君）治疗由动脉高血压和动脉粥样硬化引起的慢性CVD患者的临床疗效进行了一项开放对照研究。主要组包括30名（60%）患者，除常规基础治疗外，每天给予1000毫克米多君（米多君）。对照组由20名（40%）仅接受常规基础治疗的患者组成。研究持续时间为60天。为评估米多君（米多君）的临床疗效，在患者纳入研究时（）、治疗开始后的第11天和第60天，对主要主观临床症状、神经、心理情绪和认知状态、生活质量进行了评估。为评估米多君（米多君）对血管内皮的影响，在患者纳入研究时、治疗开始后的第11天和第60天，测定血液中的不对称二甲基精氨酸（ADMA）、组织纤溶酶原激活剂（tPA）、纤溶酶原激活剂抑制剂-1（PAI-1）和内皮素-1。
米多君（米多君）对主要临床症状和认知功能有积极治疗作用，表现为提高心理活动速度、改善短期和操作记忆、增强心理过程和记忆痕迹对干扰影响的抵抗力以及改善认知诱发电位P300结果。米多君（米多君）治疗导致状态和特质焦虑水平降低。接受米多君（米多君）治疗的患者的生活质量因身体和心理成分而提高。已确定米多君（米多君）对降低内皮素-1和PAI-1水平的作用，这表明该药物具有抗血栓形成作用。
证明了米多君（米多君）对慢性CVD患者具有益智、抗焦虑和抗血栓形成作用，这使得专家们有可能在临床实践中推荐该药物广泛使用。
